April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
LOXL1 Gene Sequence Variants and Vascular Disease in Exfoliation Syndrome and Exfoliative Glaucoma
Author Affiliations & Notes
  • G. Hollo
    Dept of Ophthalmology,
    Semmelweis University, Budapest, Hungary
  • A. Gal
    Clinical and Research Centre for Molecular Neurology,
    Semmelweis University, Budapest, Hungary
  • P. Kothy
    Dept of Ophthalmology,
    Semmelweis University, Budapest, Hungary
  • J. M. Molnar
    Clinical and Research Centre for Molecular Neurology,
    Semmelweis University, Budapest, Hungary
  • Footnotes
    Commercial Relationships  G. Hollo, None; A. Gal, None; P. Kothy, None; J.M. Molnar, None.
  • Footnotes
    Support  Hungarian National Health Grant (ETT) 001/2009 (Dr. Holló)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2192. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Hollo, A. Gal, P. Kothy, J. M. Molnar; LOXL1 Gene Sequence Variants and Vascular Disease in Exfoliation Syndrome and Exfoliative Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2192.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To investigate whether the single nucleotide polymorphisms (SNPs) of the LOXL1 gene associated with exfoliation syndrome (XFS) and exfoliative glaucoma (XFG) are different in XFS/XFG patients with and without cardiovascular disease (CVD); and to compare the allele frequencies in XFS/XFG with those in ischemic cerebrovascular disease (stroke), in the Hungarian population.

 
Methods:
 

G153D and R141L allele frequencies were determined for 56 XFS/XFG patients (10 patients with and 45 without CVD, 1 patient unclassified), and for 189 patients with stroke.

 
Results:
 

For G153D the frequencies of guanine (G) and adenine (A) alleles were 71.4% and 28.6% in the ischemic stroke group, and 58.0% and 42.0% in XFS/XFG (Chi-square test, p=0.008). The corresponding figures in XFS/XFG without CVD were 56.7% and 43.3%, and 60.0% and 40.0% in XFS/XFG with CVD (p=0.785). For R141L the frequencies of G and timidine (T) alleles were 68.2% and 31.7% in stroke patients, and 82.1% and 17.9% in XFS/XFG (p=0.004). No difference was seen for allele frequency distribution between XFS/XFG patients without and with CVD (84.4% and 15.6%; 80.0% and 20.0%, respectively, p=0.738).

 
Conclusions:
 

In Hungarians, the frequency of G (risk) allele of G153D SNP is low in XFS/XFG. The frequency of G allele in R141L and G153D SNPs of the LOXL1 gene does not differ between XFS/XFG patients with and without CVD, but its frequency is different in XFS/XFG and ischemic stroke. These results suggest that the G allele in these SNPs has no direct role in the development of vascular diseases associated with XFS/XFG.  

 
Keywords: clinical (human) or epidemiologic studies: risk factor assessment • ischemia • genetics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×